Quercetin-gavaging quashes anaphylaxis sequela in the peanut sensitised wistars
© Behroo et al; licensee BioMed Central Ltd. 2015
Published: 30 March 2015
Regarding the large figures of patients affected with potentially life-threatening peanut allergy, the possibility of inevitable occurrence of unexpected exposures and, the paucity of promising acceptable immunotherapy approaches, more applicable and at the same time, safe remedial strategies are necessitated.
Quercetin, a nutritional panacea belonging to “Flavonol” sub-group of the flavonoid family, thanks to its antioxidant/free radical-scavenging, anti-inflammatory and other protective properties has been suggested for therapy of humankind allergic diseases and might be helpful for the treatment of food allergies.
The main aim of our study was to investigate the anti-aanaphylactic characteristics of quercetin in a wistar-rat model of peanut allergy.
Material and methods
40 male wistar rats, 4-6 weeks old at study start, were sensitized with crude peanut herape in the presence of cholera toxin adjuvant. The sensitized rats in the treatment group (n= 10), were treated intragastrically with quercetin, at a dose of 50 mg/Kg.BW over a period of four weeks. Subsequently, some well-known anaphylaxis-determinant variables were measured.
Following calculations, it was revealed that quercetin has sufficiently abrogated peanut-induced anaphylactic reactions. Accordingly, plasma histamine and total serum IgE levels had been lowered significantly, in treatment group (p< 0.000 and p<0.000, respectively). Additionally, all of the intradermal- and intraperitoneal-challenge test-results were negative in the quercetin-treated animals.
Our results approved that a naturally-occurring flavonoid, Quercetin, has been efficient enough to curb the peanut allergy complications in a wistar model and can be considered as a secure preventative/prophylactic/herapeutic compound in populations suffering from potentially deathful IgE-mediated food allergies.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.